Live
- Stage set for counting of votes for Jharkhand Assembly elections
- MLA Sri Ganesh Engages ASHA Workers and Resource Persons in Caste Census Meeting
- Supreme Court verdict on validity of Preamble modification in 1976 likely on November 25
- ‘Zebra’ movie review: A gripping tale of banking fraud and redemption
- Saurabh Netravalkar, Unmukt Chand, Dwayne Smith and Rahkeem Cornwall headline USPL
- NPP asks members not to attend meeting called by Biren govt
- Bulls roar on Dalal Street, Sensex and Nifty up over 2 pc
- Over 880,000 people displaced in Lebanon, food security deteriorates: UN
- BGT 2024-25: Bumrah picks 4-17 as Australia trail India by 83 runs in 17-wicket day
- Calcutta High Court stays order on demolition of hotels in Bengal’s Mandarmani
SKorea approves use of 1st homegrown COVID-19 vaccine from SK Bioscience
SKorea approves use of 1st homegrown COVID-19 vaccine from SK Bioscience
South Korea on Wednesday approved the use of SKYCovione, the country's first homegrown COVID-19 vaccine developed by SK Bioscience Co., taking a major step toward achieving vaccine sovereignty in the fight against the pandemic.
Seoul: South Korea on Wednesday approved the use of SKYCovione, the country's first homegrown COVID-19 vaccine developed by SK Bioscience Co., taking a major step toward achieving vaccine sovereignty in the fight against the pandemic.
The Ministry of Food and Drug Safety (MFDS) said it approved the use of SKYCovione, also known as GBP510, through consultations of the ministry's Final Inspection Committee, following an "item approval" recommendation by MFDS' Central Pharmaceutical Affairs Council on Monday, Yonhap news agency reported.
SKYCovione is the country's first homegrown vaccine to have successfully completed all three phases of its clinical trial. SK Bioscience conducted a phase-three clinical trial on some 4,000 adults in six countries -- Thailand, Vietnam, New Zealand, Ukraine, the Philippines and South Korea.
It is a recombinant-protein vaccine based on novel two-component nanoparticles that can maximize the immune effect. It was jointly developed with the Institute for Protein Design at the University of Washington.
The vaccine has been designed for recipients to receive two doses in a four-week interval.
